KUALA LUMPUR, Jan 15 -- Privately-held cell manufacturing platform technology company, RoosterBio Inc has announced signing a strategic collaboration with Sartorius to advance cell and gene therapy manufacturing.
RoosterBio is a leading supplier of human mesenchymal stem/stromal cell (hMSC) working cell banks, highly engineered media and hMSC bioprocess systems, while Sartorius is a leading international partner of life science research and the biopharmaceutical industry.
The collaboration aims to advance scale-up of hMSC manufacturing for regenerative medicine by leveraging best-in-class solutions of both companies to significantly reduce process development efforts, industrialise supply chain and accelerate development and commercialisation of groundbreaking cell-based regenerative cures.
RoosterBio and Sartorius will create a set of GMP-compatible, customer-centric protocols using RoosterBio’s hMSC and media systems, alongside Sartorius’s single use manufacturing technologies, process control software and cell analysis tools of hMSC final product manufacturing.
According to a statement, cell expansion will be rapidly optimised using Sartorius’s benchtop Ambr® system and MODDE® design of experiment software, allowing the technical team to compare cultures in identically sized, multi-parallel bioreactors to gain process information and optimised conditions in a short timeline.
This joint effort will simplify multiple steps in therapeutic development by providing robust, streamlined, end-to-end platform technologies and protocols that can be implemented for rapid scale up of manufacturing processes, allowing product developers to significantly speed up their development timelines.
Both companies aim to use the data from this collaboration to provide co-learning and development opportunities to support the growing cell and gene therapy industry.
-- BERNAMA
No comments:
Post a Comment